Data Sheet (Cat.No.T14487)

TargetMol

AZM475271

Chemical Properties



CAS No. : 476159-98-5

Formula: C23H27ClN4O3

Molecular Weight: 442.94

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	AZM475271 is a potent and selective inhibitor of Src kinase (IC50: 5 nM).
Targets(IC50)	Apoptosis,Others,Src
In vitro	AZM475271 demonstrated strong dose-dependent inhibition of Src tyrosine kinase activity in the L3.6pl human pancreatic carcinoma cell line. The IC50 concentration of AZM475271 to inhibit the phosphorylation of c-src, lck, and c-yes was 0.01, 0.03, and 0.08 μmol/L, respectively, in comparison with an IC50 of 0.7 μmol/L AZM475271 to inhibit KDR [2]. Maximum reduction of Src kinase activity was observed after incubation for 4 hours with ≥5 μmol/L.
In vivo	Treatment with gemcitabine or AZM475271 alone did not significantly change animal weight [2]. In vivo: Tumors appeared to be palpable at day 14 after tumor cell injection in all animals except mice treated with both AZM475271 and gemcitabine, in which the earliest possible palpation of the tumors was at day 17 after tumor cell injection.

Solubility Information

Solubility	DMSO: 42 mg/mL (94.82 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2576 mL	11.2882 mL	22.5764 mL
5 mM	0.4515 mL	2.2576 mL	4.5153 mL
10 mM	0.2258 mL	1.1288 mL	2.2576 mL
50 mM	0.0452 mL	0.2258 mL	0.4515 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Plé PA, et al. Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src. J Med Chem. 2004 Feb 12;47(4):871-87.
Yezhelyev MV, et al. Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res. 2004 Dec 1;10(23):8028-36.